This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guo, Z. S. Articles by Bartlett, D. L. Search for Related Content PubMed PubMed Citation Articles by Guo, Z. S. Articles by Bartlett, D. L.

The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Antiapoptosis Genes SPI-1 and SPI-2

¹ Division of Surgical Oncology, University of Pittsburgh Cancer Institute and Department of Surgery, School of Medicine; ² Molecular Medicine Institute, University of Pittsburgh, Pittsburgh, Pennsylvania; ³ Surgery Branch, Center for Cancer Research, National Cancer Institute; ⁴ Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland; and ⁵ Department of Hepatobiliary Surgery, First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China

Requests for reprints: David L. Bartlett, Division of Surgical Oncology, University of Pittsburgh Cancer Institute, Room 460, The Cancer Pavilion, 5150 Center Avenue, Pittsburgh, PA 15232. Phone: 412-692-2852; Fax: 412-692-2520; E-mail: guozs{at}upmc.edu.

The ability of cancer cells to evade apoptosis may permit survival of a recombinant vaccinia lacking antiapoptotic genes in cancer cells compared with normal cells. We have explored the deletion of two vaccinia virus host range/antiapoptosis genes, SPI-1 and SPI-2, for their effects on the viral replication and their ability to induce cell death in infected normal and transformed cells in vitro. Indeed, in three paired normal and transformed cell types, the SPI-1 and SPI-2 gene-deleted virus (vSP) preferentially replicates in transformed cells or p53-null cells when compared with their normal counterparts. This selectivity may be derived from the fact that vSP-infected normal cells died faster than infected cancer cells. A fraction of infected cells died with evidence of necrosis as shown by both flow cytometry and detection of high-mobility group B1 protein released from necrotic cells into the culture supernatant. When administered to animals, vSP retains full ability to replicate in tumor tissues, whereas replication in normal tissues is greatly diminished. In a model of viral pathogenesis, mice treated with vSP survived substantially longer when compared with mice treated with the wild-type virus. The mutant virus vSP displayed significant antitumoral effects in an MC38 s.c. tumor model in both nude (P < 0.001) and immunocompetent mice (P < 0.05). We conclude that this recombinant vaccinia vSP shows promise for oncolytic virus therapy. Given its enhanced tumor selectivity, improved safety profile, and substantial oncolytic effects following systemic delivery in murine models, it should also serve as a useful vector for tumor-directed gene therapy.

This article has been cited by other articles:

				T.-C. Liu, H. Wakimoto, R. L. Martuza, and S. D. Rabkin Herpes Simplex Virus Us3( ) Mutant as Oncolytic Strategy and Synergizes with Phosphatidylinositol 3-Kinase-Akt Targeting Molecular Therapeutics Clin. Cancer Res., October 1, 2007; 13(19): 5897 - 5902. [Abstract] [Full Text] [PDF]

				M. M. Stanford, J. W. Barrett, S. H. Nazarian, S. Werden, and G. McFadden Oncolytic Virotherapy Synergism with Signaling Inhibitors: Rapamycin Increases Myxoma Virus Tropism for Human Tumor Cells J. Virol., February 1, 2007; 81(3): 1251 - 1260. [Abstract] [Full Text] [PDF]

				Y. Chernajovsky, L. Layward, and N. Lemoine Fighting cancer with oncolytic viruses BMJ, January 21, 2006; 332(7534): 170 - 172. [Full Text] [PDF]